Group 1 - The core viewpoint of the news highlights the performance of the medical and healthcare innovation sector, with the CSI Medical and Healthcare Innovation Index showing a slight increase of 0.41% as of February 5, 2026, and several key stocks like Aimeike and Jinfo Bio experiencing notable gains [1] - The public fund's holding in pharmaceutical stocks decreased to 7.95% in Q4 2025, down by 2.58 percentage points from the previous quarter, while the medical R&D outsourcing sector maintained a strong position with a 16.4% holding [1] - Donghai Securities indicates that the innovative drug sector is entering a phase of accelerated profit realization, with strong performance validating the effectiveness of domestic innovative drug business models, and suggests focusing on companies with solid profitability and differentiated core products [1] Group 2 - The CSI Medical and Healthcare Innovation Index consists of 30 listed companies selected for their profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented companies in the medical and healthcare sector [2] - As of January 30, 2026, the top ten weighted stocks in the CSI Medical and Healthcare Innovation Index accounted for 63.9% of the index, with notable companies including WuXi AppTec, Mindray Medical, and Heng Rui Medicine [2]